Amgen’s most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $200.00 short put and a strike $195.00 long put offers a potential 11.61% return on risk over the next 16 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $200.00 by expiration. The full premium credit of $0.52 would be kept by the premium seller. The risk of $4.48 would be incurred if the stock dropped below the $195.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.
The RSI indicator is at 67.68 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Amgen antibody shows promise in myeloma trial, gets FDA fast track
Tue, 04 Dec 2018 05:23:15 +0000
Amgen Inc (AMGN.O), updating the first trial of its bispecific antibody for multiple myeloma, said on Monday seven out of 10 patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer. Six patients were still responding at 7.5 months of follow-up, according to research presented in San Diego at the annual meeting of the American Society of Haematology (ASH). Amgen said AMG420, which targets a protein linked to multiple myeloma known as BCMA, has been given fast track status by the U.S. Food and Drug Administration.
Amgen Announces First-In-Human Data Evaluating Investigational Novel BiTE® Immunotherapies AMG 420 And AMG 330 At ASH 2018
Tue, 04 Dec 2018 02:15:00 +0000
THOUSAND OAKS, Calif., Dec. 3, 2018 /PRNewswire/ — Amgen (AMGN) today announced the first clinical results from studies evaluating investigational novel bispecific T cell engager (BiTE®) immunotherapies AMG 420 and AMG 330. In two separate Phase 1 dose escalation studies, AMG 420, which targets B-cell maturation antigen (BCMA), and AMG 330, which targets CD33, provided early evidence of tolerability and anti-tumor activity in patients with relapsed and/or refractory multiple myeloma and relapsed or refractory acute myeloid leukemia (AML), respectively.
Amgen To Present At The Citi Global Healthcare Conference
Mon, 03 Dec 2018 21:00:00 +0000
THOUSAND OAKS, Calif. , Dec. 3, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) will present at the Citi Global Healthcare Conference at 12:35 p.m. ET on Thursday , Dec. 6, 2018, in New York City . Elliott M. …
Amgen Falls 3%
Mon, 03 Dec 2018 20:36:02 +0000
Investing.com – Amgen (NASDAQ:AMGN) fell by 3.03% to trade at $201.94 by 13:35 (18:35 GMT) on Monday on the NASDAQ exchange.
Could Amgen Inc’s (NASDAQ:AMGN) Investor Composition Influence The Stock Price?
Mon, 03 Dec 2018 15:18:08 +0000
Every investor in Amgen Inc (NASDAQ:AMGN) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it’s not unusual to see insiders
Also on Market Tamer…
Follow Us on Facebook